{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T06:28:51Z","timestamp":1762064931678,"version":"build-2065373602"},"reference-count":173,"publisher":"IMR Press","issue":"9","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Thousand Young Talents Program of China, the National Natural Science Foundation of China","award":["31770795","81974514"],"award-info":[{"award-number":["31770795","81974514"]}]},{"DOI":"10.13039\/501100004479","name":"Jiangxi Province Natural Science Foundation","doi-asserted-by":"crossref","award":["20181ACB20014"],"award-info":[{"award-number":["20181ACB20014"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of Coronavirus disease 2019 (COVID-19), which was announced as a pandemic leading to devastating economic and medical burden worldwide. The virus attacks the organ system across the body by binding to its receptor (for example, angiotensin converting enzyme 2) on the surface of the host cell of various organs. The patients present with a variety of pathological symptoms ranging from fever, cough and cytokine storm to acute respiratory distress syndrome (ARDS). Many combination therapies have been developed to combat the disease, via blocking one or more processes of the viral life cycle and\/or relieving host complications simultaneously. In this review, the progress of those combination therapies containing at least one small molecule is updated. We believe it\u2019ll provide significant inspiration for further development of treatment strategy against SARS-CoV-2, especially its mutant variants.<\/jats:p>","DOI":"10.31083\/j.fbl2709257","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T10:00:48Z","timestamp":1662717648000},"source":"Crossref","is-referenced-by-count":3,"title":["Combination Therapies against COVID-19"],"prefix":"10.31083","volume":"27","author":[{"given":"Qunfeng","family":"Luo","sequence":"first","affiliation":[{"name":"School of Basic Medical Sciences, Nanchang University, 330047 Nanchang, Jiangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunxi","family":"Zheng","sequence":"first","affiliation":[{"name":"Queen Marry College, Nanchang University, 330047 Nanchang, Jiangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zhang","sequence":"first","affiliation":[{"name":"School of Basic Medical Sciences, Nanchang University, 330047 Nanchang, Jiangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Poduri R, Joshi G, Jagadeesh G. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. Cellular Signalling. 2020; 74: 109721.","DOI":"10.1016\/j.cellsig.2020.109721"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181: 271\u2013280.e8.","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020; 367: 1444\u20131448.","DOI":"10.1126\/science.abb2762"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Brielle ES, Schneidman-Duhovny D, Linial M. The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor. Viruses. 2020; 12: 497.","DOI":"10.3390\/v12050497"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proceedings of the National Academy of Sciences. 2009; 106: 5871\u20135876.","DOI":"10.1073\/pnas.0809524106"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Millet JK, Whittaker GR. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proceedings of the National Academy of Sciences. 2014; 111: 15214\u201315219.","DOI":"10.1073\/pnas.1407087111"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Park J, Li K, Barlan A, Fehr AR, Perlman S, McCray PB, et al. Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proceedings of the National Academy of Sciences. 2016; 113: 12262\u201312267.","DOI":"10.1073\/pnas.1608147113"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Gierer S, Bertram S, Kaup F, Wrensch F, Heurich A, Kr\u00e4mer-K\u00fchl A, et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. Journal of Virology. 2013; 87: 5502\u20135511.","DOI":"10.1128\/JVI.00128-13"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Research. 2020; 176: 104742.","DOI":"10.1016\/j.antiviral.2020.104742"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Essalmani R, Jain J, Susan-Resiga D, Andr\u00e9o U, Evagelidis A, Derbali RM, et al. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity. Journal of Virology. 2022; 96: e0012822.","DOI":"10.1128\/jvi.00745-22"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Liu T, Luo S, Libby P, Shi GP. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. Pharmacology & Therapeutics. 2020; 213: 107587.","DOI":"10.1016\/j.pharmthera.2020.107587"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Lempp FA, Soriaga LB, Montiel-Ruiz M, Benigni F, Noack J, Park Y, et al. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature. 2021; 598: 342\u2013347.","DOI":"10.1038\/s41586-021-03925-1"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Amraei R, Yin W, Napoleon MA, Suder EL, Berrigan J, Zhao Q, et al. CD209L\/L-SIGN and CD209\/DC-SIGN Act as Receptors for SARS-CoV-2. ACS Central Science. 2021; 7: 1156\u20131165.","DOI":"10.1021\/acscentsci.0c01537"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020; 370: 856\u2013860.","DOI":"10.1126\/science.abd2985"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Kim D, Lee J, Yang J, Kim JW, Kim VN, Chang H. The Architecture of SARS-CoV-2 Transcriptome. Cell. 2020; 181: 914\u2013921.e10.","DOI":"10.1016\/j.cell.2020.04.011"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Redondo N, Zald\u00edvar-L\u00f3pez S, Garrido JJ, Montoya M. SARS-CoV-2 Accessory Proteins in Viral Pathogenesis: Knowns and Unknowns. Frontiers in Immunology. 2021; 12: 708264.","DOI":"10.3389\/fimmu.2021.708264"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science. 2020; 368: 409\u2013412.","DOI":"10.1126\/science.abb3405"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020; 368: 779\u2013782.","DOI":"10.1126\/science.abb7498"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Al-Horani RA, Kar S, Aliter KF. Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. International Journal of Molecular Sciences. 2020; 21: 5224.","DOI":"10.3390\/ijms21155224"},{"key":"ref20","unstructured":"Malik YA. Properties of Coronavirus and SARS-CoV-2. The Malaysian Journal of Pathology. 2020; 42: 3\u201311."},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Wassie GT, Azene AG, Bantie GM, Dessie G, Aragaw AM. Incubation Period of Severe Acute Respiratory Syndrome Novel Coronavirus 2 that Causes Coronavirus Disease 2019: a Systematic Review and Meta-Analysis. Current Therapeutic Research. 2020; 93: 100607.","DOI":"10.1016\/j.curtheres.2020.100607"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Frontiers of Medicine. 2020; 14: 126\u2013135.","DOI":"10.1007\/s11684-020-0767-8"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Azhar EI, Hui DSC, Memish ZA, Drosten C, Zumla A. The Middle East Respiratory Syndrome (MERS). Infectious Disease Clinics of North America. 2019; 33: 891\u2013905.","DOI":"10.1016\/j.idc.2019.08.001"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Wu F, Zhao S, Yu B, Chen Y, Wang W, Song Z, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579: 265\u2013269.","DOI":"10.1038\/s41586-020-2008-3"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395: 497\u2013506.","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. a Retrospective Observational Study. American Journal of Respiratory and Critical Care Medicine. 2020; 201: 1372\u20131379.","DOI":"10.1164\/rccm.202003-0543OC"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 2020; 382: 1708\u20131720.","DOI":"10.1056\/NEJMoa2002032"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus\u2013Infected Pneumonia in Wuhan, China. Journal of the American Medical Association. 2020; 323: 1061\u20131069.","DOI":"10.1001\/jama.2020.1585"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Hikmet F, M\u00e9ar L, Edvinsson \u00c5, Micke P, Uhl\u00e9n M, Lindskog C. The protein expression profile of ACE2 in human tissues. Molecular Systems Biology. 2020; 16: e9610.","DOI":"10.15252\/msb.20209610"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Faqihi F, Alharthy A, Alodat M, Kutsogiannis DJ, Brindley PG, Karakitsos D. Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: a pilot study. Journal of Critical Care. 2020; 60: 328\u2013333.","DOI":"10.1016\/j.jcrc.2020.07.001"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Alharthy A, Faqihi F, Memish ZA, Karakitsos D. Lung Injury in COVID-19\u2014an Emerging Hypothesis. ACS Chemical Neuroscience. 2020; 11: 2156\u20132158.","DOI":"10.1021\/acschemneuro.0c00422"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. Journal of the American Medical Association. 2020; 323: 1574\u20131581.","DOI":"10.1001\/jama.2020.5394"},{"key":"ref33","unstructured":"Waqar W, Ismail S, Jamil Z, Al-Shehhi A, Imran M, Hetta HF, et al. SARS-CoV-2 associated pathogenesis, immune dysfunction and involvement of host factors: a comprehensive review. European Review for Medical and Pharmacological Sciences. 2021; 25: 7526\u20137542."},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). Journal of General Internal Medicine. 2020; 35: 1545\u20131549.","DOI":"10.1007\/s11606-020-05762-w"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine. 2020; 46: 846\u2013848.","DOI":"10.1007\/s00134-020-05991-x"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Baig AM, Sanders EC. Potential neuroinvasive pathways of SARS\u2010CoV\u20102: Deciphering the spectrum of neurological deficit seen in coronavirus disease\u20102019 (COVID\u201019). Journal of Medical Virology. 2020; 92: 1845\u20131857.","DOI":"10.1002\/jmv.26105"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Li Y, Bai W, Hashikawa T. The neuroinvasive potential of SARS\u2010CoV2 may play a role in the respiratory failure of COVID\u201019 patients. Journal of Medical Virology. 2020; 92: 552\u2013555.","DOI":"10.1002\/jmv.25728"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical Characteristics of COVID-19 Patients with Digestive Symptoms in Hubei, China: a Descriptive, Cross-Sectional, Multicenter Study. American Journal of Gastroenterology. 2020; 115: 766\u2013773.","DOI":"10.14309\/ajg.0000000000000620"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Edwards K, Hussain I. Two Cases of Severe Autoimmune Thyrotoxicosis Following SARS-CoV-2 Infection. Journal of Investigative Medicine High Impact Case Reports. 2021; 9: 232470962110564.","DOI":"10.1177\/23247096211056497"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Jang WD, Jeon S, Kim S, Lee SY. Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. Proceedings of the National Academy of Sciences. 2021; 118: e2024302118.","DOI":"10.1073\/pnas.2024302118"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Bocci G, Bradfute SB, Ye C, Garcia MJ, Parvathareddy J, Reichard W, Surendranathan S, Bansal S, Bologa CG, Perkins DJ, Jonsson CB, Sklar LA, Oprea TI. Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19. ACS Pharmacology & Translational Science. 2020; 3: 1278\u20131292.","DOI":"10.1021\/acsptsci.0c00131"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"McCullough PA, Alexander PE, Armstrong R, Arvinte C, Bain AF, Bartlett RP, et al. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Reviews in Cardiovascular Medicine. 2020; 21: 517\u2013530.","DOI":"10.31083\/j.rcm.2020.04.264"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Al-Hajeri H, Baroun F, Abutiban F, Al-Mutairi M, Ali Y, Alawadhi A, et al. Therapeutic role of immunomodulators during the COVID-19 pandemic\u2013 a narrative review. Postgraduate Medicine. 2022; 134: 160\u2013179.","DOI":"10.1080\/00325481.2022.2033563"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee S, Chakraborty C. Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: need to Know more. Archives of Medical Research. 2020; 51: 585\u2013586.","DOI":"10.1016\/j.arcmed.2020.05.001"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 \u2014 Final Report. New England Journal of Medicine. 2020; 383: 1813\u20131826.","DOI":"10.1056\/NEJMoa2007764"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Lamb YN. Remdesivir: first Approval. Drugs. 2020; 80: 1355\u20131363.","DOI":"10.1007\/s40265-020-01378-w"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Wilt TJ, Kaka AS, MacDonald R, Greer N, Obley A, Duan-Porter W. Remdesivir for Adults with COVID-19: A Living Systematic Review for American College of Physicians Practice Points. Annals of Internal Medicine. 2021; 174: 209\u2013220.","DOI":"10.7326\/M20-5752"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Rahimi MM, Jahantabi E, Lotfi B, Forouzesh M, Valizadeh R, Farshid S. Renal and liver injury following the treatment of COVID-19 by remdesivir. Journal of Nephropathology. 2021; 10: e10.","DOI":"10.34172\/jnp.2021.10"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"G\u00e9rard AO, Laurain A, Fresse A, Parassol N, Muzzone M, Rocher F, et al. Remdesivir and Acute Renal Failure: a Potential Safety Signal from Disproportionality Analysis of the who Safety Database. Clinical Pharmacology & Therapeutics. 2021; 109: 1021\u20131024.","DOI":"10.1002\/cpt.2145"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. The New England Journal of Medicine. 2021; 384: 497\u2013511.","DOI":"10.1056\/NEJMoa2023184"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Narayanan A, Narwal M, Majowicz SA, Varricchio C, Toner SA, Ballatore C, et al. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. Communications Biology. 2022; 5: 169.","DOI":"10.1038\/s42003-022-03090-9"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Fu L, Ye F, Feng Y, Yu F, Wang Q, Wu Y, et al. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nature Communications. 2020; 11: 4417.","DOI":"10.1038\/s41467-020-18233-x"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Li P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, et al. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Research. 2022; 32: 322\u2013324.","DOI":"10.1038\/s41422-022-00618-w"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Hattori S, Higashi-Kuwata N, Hayashi H, Allu SR, Raghavaiah J, Bulut H, et al. A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nature Communications. 2021; 12: 668.","DOI":"10.1038\/s41467-021-20900-6"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Li Q, Yi D, Lei X, Zhao J, Zhang Y, Cui X, et al. Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase. Acta Pharmaceutica Sinica B. 2021; 11: 1555\u20131567.","DOI":"10.1016\/j.apsb.2021.02.011"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Sadeghi A, Ali Asgari A, Norouzi A, Kheiri Z, Anushirvani A, Montazeri M, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. Journal of Antimicrobial Chemotherapy. 2020; 75: 3379\u20133385.","DOI":"10.1093\/jac\/dkaa334"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Eslami G, Mousaviasl S, Radmanesh E, Jelvay S, Bitaraf S, Simmons B, et al. The impact of sofosbuvir\/daclatasvir or ribavirin in patients with severe COVID-19. Journal of Antimicrobial Chemotherapy. 2020; 75: 3366\u20133372.","DOI":"10.1093\/jac\/dkaa331"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Abbaspour Kasgari H, Moradi S, Shabani AM, Babamahmoodi F, Davoudi Badabi AR, Davoudi L, et al. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. Journal of Antimicrobial Chemotherapy. 2020; 75: 3373\u20133378.","DOI":"10.1093\/jac\/dkaa332"},{"key":"ref59","unstructured":"Izzi A, Messina V, Rinaldi L, Maggi P. Editorial - Sofosbuvir\/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents. European Review for Medical and Pharmacological Sciences. 2020; 24: 5193\u20135194."},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Sayad B, Khodarahmi R, Najafi F, Miladi R, Mohseni Afshar Z, Mansouri F, et al. Efficacy and safety of sofosbuvir\/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial. Journal of Antimicrobial Chemotherapy. 2021; 76: 2158\u20132167.","DOI":"10.1093\/jac\/dkab152"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Khalil MI, Salih MA, Mustafa AA. Broad beans (Vicia faba) and the potential to protect from COVID-19 coronavirus infection. Sudanese Journal of Paediatrics. 2020; 20: 10\u201312.","DOI":"10.24911\/SJP.1061585398078"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Toelzer C, Gupta K, Yadav SKN, Borucu U, Davidson AD, Kavanagh Williamson M, et al. Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. Science. 2020; 370: 725\u2013730.","DOI":"10.1126\/science.abd3255"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Li J, Xu D, Wang L, Zhang M, Zhang G, Li E, et al. Glycyrrhizic Acid Inhibits SARS-CoV-2 Infection by Blocking Spike Protein-Mediated Cell Attachment. Molecules. 2021; 26: 6090.","DOI":"10.3390\/molecules26206090"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Caliebe RH, Scior T, Ammon HPT. Binding of boswellic acids to functional proteins of the SARS\u2010CoV\u20102 virus: Bioinformatic studies. Archiv Der Pharmazie. 2021; 354: e2100160.","DOI":"10.1002\/ardp.202100160"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Gomaa AA, Mohamed HS, Abd-ellatief RB, Gomaa MA, Hammam DS. Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID-19 infection: a randomized clinical trial. Inflammopharmacology. 2022; 30: 477\u2013486.","DOI":"10.1007\/s10787-022-00939-7"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Ohashi H, Watashi K, Saso W, Shionoya K, Iwanami S, Hirokawa T, et al. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. IScience. 2021; 24: 102367.","DOI":"10.1016\/j.isci.2021.102367"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Wang R, Chan JF, Wang S, Li H, Zhao J, Ip TK, et al. Orally administered bismuth drug together with N-acetyl cysteine as a broad-spectrum anti-coronavirus cocktail therapy. Chemical Science. 2021; 13: 2238\u20132248.","DOI":"10.1039\/D1SC04515F"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Mahase E. Covid-19: UK becomes first country to authorise antiviral molnupiravir. British Medical Journal. 2021; 375: n2697.","DOI":"10.1136\/bmj.n2697"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID-19: A systematic review of literature. Diabetology & Metabolic Syndrome. 2021; 15: 102329.","DOI":"10.1016\/j.dsx.2021.102329"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Hahn F, Wangen C, H\u00e4ge S, Peter AS, Dobler G, Hurst B, et al. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro. Viruses. 2020; 12: 1394.","DOI":"10.3390\/v12121394"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Biering SB, Van Dis E, Wehri E, Yamashiro LH, Nguyenla X, Dugast-Darzacq C, et al. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2. ACS Infectious Diseases. 2021; 7: 2337\u20132351.","DOI":"10.1021\/acsinfecdis.1c00017"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Choy K, Wong AY, Kaewpreedee P, Sia SF, Chen D, Hui KPY, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Research. 2020; 178: 104786.","DOI":"10.1016\/j.antiviral.2020.104786"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. New England Journal of Medicine. 2021; 384: 795\u2013807.","DOI":"10.1056\/NEJMoa2031994"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Mesa RA. Tipifarnib: farnesyl transferase inhibition at a crossroads. Expert Review of Anticancer Therapy. 2006; 6: 313\u2013319.","DOI":"10.1586\/14737140.6.3.313"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Munster P, Aggarwal R, Hong D, Schellens JHM, van der Noll R, Specht J, et al. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class i Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clinical Cancer Research. 2016; 22: 1932\u20131939.","DOI":"10.1158\/1078-0432.CCR-15-1665"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Kongsomros S, Suksatu A, Kanjanasirirat P, Manopwisedjaroen S, Prasongtanakij S, Jearawuttanakul K, et al. Anti-SARS-CoV-2 Activity of Extracellular Vesicle Inhibitors: Screening, Validation, and Combination with Remdesivir. Biomedicines. 2021; 9: 1230.","DOI":"10.3390\/biomedicines9091230"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Pohl MO, Busnadiego I, Marrafino F, Wiedmer L, Hunziker A, Fernbach S, et al. Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir. Journal of General Virology. 2021; 102: 001625.","DOI":"10.1099\/jgv.0.001625"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Deng Q, Rasool RU, Russell RM, Natesan R, Asangani IA. Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19. iScience. 2021; 24: 102254.","DOI":"10.1016\/j.isci.2021.102254"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Zhang Q, Chen CZ, Swaroop M, Xu M, Wang L, Lee J, et al. Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discovery. 2020; 6: 80.","DOI":"10.1038\/s41421-020-00222-5"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Brunotte L, Zheng S, Mecate-Zambrano A, Tang J, Ludwig S, Rescher U, Schloer S. Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro. Pharmaceutics. 2021; 13: 1400.","DOI":"10.3390\/pharmaceutics13091400"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Gautret P, Lagier J, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents. 2020; 56: 105949.","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Lagier J, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine\/azithromycin and other regimens in Marseille, France: a retrospective analysis. Travel Medicine and Infectious Disease. 2020; 36: 101791.","DOI":"10.1016\/j.tmaid.2020.101791"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. M\u00e9Decine Et Maladies Infectieuses. 2020; 50: 384.","DOI":"10.1016\/j.medmal.2020.03.006"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Ramireddy A, Chugh H, Reinier K, Ebinger J, Park E, Thompson M, et al. Experience with Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring. Journal of the American Heart Association. 2020; 9: e017144.","DOI":"10.1161\/JAHA.120.017144"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Kang CK, Seong M, Choi S, Kim TS, Choe PG, Song SH, et al. In vitro activity of lopinavir\/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses. The Korean Journal of Internal Medicine. 2020; 35: 782\u2013787.","DOI":"10.3904\/kjim.2020.157"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Abd-Elsalam S, Soliman S, Esmail ES, Khalaf M, Mostafa EF, Medhat MA, et al. Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial. Biological Trace Element Research. 2021; 199: 3642\u20133646.","DOI":"10.1007\/s12011-020-02512-1"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Calistri A, Luganini A, Mognetti B, Elder E, Sibille G, Conciatori V, et al. The New Generation hDHODH Inhibitor MEDS433 Hinders the In Vitro Replication of SARS-CoV-2 and Other Human Coronaviruses. Microorganisms. 2021; 9: 1731.","DOI":"10.3390\/microorganisms9081731"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry. Journal of Virology. 2012; 86: 6537\u20136545.","DOI":"10.1128\/JVI.00094-12"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Raschi E, Caraceni P, Poluzzi E, De Ponti F. Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19? Expert Opinion on Drug Safety. 2020; 19: 1367\u20131369.","DOI":"10.1080\/14740338.2020.1812191"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Tsuchiya K, Fujisawa T, Mochizuka Y, Takuma S, Oishi K, Endo Y, et al. Transient leukocytopenia following combination therapy for COVID-19. Respiratory Investigation. 2022; 60: 158\u2013161.","DOI":"10.1016\/j.resinv.2021.09.007"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Wang J, Pendurthi UR, Yi G, Rao LVM. SARS-CoV-2 infection induces the activation of tissue factor-mediated coagulation via activation of acid sphingomyelinase. Blood. 2021; 138: 344\u2013349.","DOI":"10.1182\/blood.2021010685"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Carpinteiro A, Edwards MJ, Hoffmann M, Kochs G, Gripp B, Weigang S, et al. Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells. Cell Reports Medicine. 2020; 1: 100142.","DOI":"10.1016\/j.xcrm.2020.100142"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Facente SN, Reiersen AM, Lenze EJ, Boulware DR, Klausner JD. Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: a Review of Current Evidence. Drugs. 2021; 81: 2081\u20132089.","DOI":"10.1007\/s40265-021-01636-5"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Reis G, dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the together randomised, platform clinical trial. The Lancet Global Health. 2022; 10: e42\u2013e51.","DOI":"10.1016\/S2214-109X(21)00448-4"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Glebov OO. Low-Dose Fluvoxamine Modulates Endocytic Trafficking of SARS-CoV-2 Spike Protein: A Potential Mechanism for Anti-COVID-19 Protection by Antidepressants. Frontiers in Pharmacology. 2021; 12: 787261.","DOI":"10.3389\/fphar.2021.787261"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Kamat S, Kumari M. Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity. Frontiers in Pharmacology. 2021; 12: 576093.","DOI":"10.3389\/fphar.2021.576093"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Okesli A, Khosla C, Bassik MC. Human pyrimidine nucleotide biosynthesis as a target for antiviral chemotherapy. Current Opinion in Biotechnology. 2017; 48: 127\u2013134.","DOI":"10.1016\/j.copbio.2017.03.010"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Mahase E. Covid-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports. British Medical Journal. 2021; 375: n2713.","DOI":"10.1136\/bmj.n2713"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Shytaj IL, Fares M, Gallucci L, Lucic B, Tolba MM, Zimmermann L, et al. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters. mBio. 2022; 13: e0370521.","DOI":"10.1128\/mbio.03705-21"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Chen J, Xia L, Liu L, Xu Q, Ling Y, Huang D, et al. Antiviral Activity and Safety of Darunavir\/Cobicistat for the Treatment of COVID-19. Open Forum Infectious Diseases. 2020; 7: ofaa241.","DOI":"10.1093\/ofid\/ofaa241"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Colunga Biancatelli RML, Berrill M, Catravas JD, Marik PE. Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19). Frontiers in Immunology. 2020; 11: 1451.","DOI":"10.3389\/fimmu.2020.01451"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Papapanou M, Papoutsi E, Giannakas T, Katsaounou P. Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19. Journal of Personalized Medicine. 2021; 11: 668.","DOI":"10.3390\/jpm11070668"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Benfield T, Bodilsen J, Brieghel C, Harboe ZB, Helleberg M, Holm C, et al. Improved Survival among Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) Treated with Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study. Clinical Infectious Diseases. 2021; 73: 2031\u20132036.","DOI":"10.1093\/cid\/ciab536"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Ye Z, Yuan S, Chan JF, Zhang AJ, Yu C, Ong CP, et al. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection. Emerging Microbes & Infections. 2021; 10: 291\u2013304.","DOI":"10.1080\/22221751.2021.1885998"},{"key":"ref105","unstructured":"D\u2019Ascanio L, Vitelli F, Cingolani C, Maranzano M, Brenner MJ, Di Stadio A. Randomized clinical trial \u201dolfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin\u201d: preliminary results. European Review for Medical and Pharmacological Sciences. 2021; 25: 4156\u20134162."},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"Robaina Cabrera CL, Keir-Rudman S, Horniman N, Clarkson N, Page C. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination. Pulmonary Pharmacology & Therapeutics. 2021; 69: 102047.","DOI":"10.1016\/j.pupt.2021.102047"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Santos S, Barata P, Charmier A, Lehmann I, Rodrigues S, Melosini MM, et al. Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy. Frontiers in Immunology. 2022; 13: 841459.","DOI":"10.3389\/fimmu.2022.841459"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Iranzo FJ, L\u00f3pez-Rodas AM, Franco L, L\u00f3pez-Rodas G. Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the \u201cCytokine Release (Storm) Syndrome\u201d Caused by SARS-CoV-2? Current Pharmaceutical Design. 2020; 26: 4515\u20134521.","DOI":"10.2174\/1381612826666200811180232"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"Caprio M, Mammi C, Rosano GM. Vitamin D: a novel player in endothelial function and dysfunction. Archives of Medical Science. 2012; 8: 4\u20135.","DOI":"10.5114\/aoms.2012.27271"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"Aini K, Fukuda D, Tanaka K, Higashikuni Y, Hirata Y, Yagi S, et al. Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice. International Heart Journal. 2019; 60: 1421\u20131429.","DOI":"10.1536\/ihj.19-117"},{"key":"ref111","doi-asserted-by":"crossref","unstructured":"Pinheiro MM, Fabbri A, Infante M. Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i). Immunotherapy. 2021; 13: 753\u2013765.","DOI":"10.2217\/imt-2020-0349"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"Farouk A, Salman S. Dapsone and doxycycline could be potential treatment modalities for COVID-19. Medical Hypotheses. 2020; 140: 109768.","DOI":"10.1016\/j.mehy.2020.109768"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduction and Targeted Therapy. 2020; 5: 293.","DOI":"10.1038\/s41392-020-00454-7"},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. Journal of Leukocyte Biology. 1997; 62: 827\u2013836.","DOI":"10.1002\/jlb.62.6.827"},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"Sharma A, Sharma C, Raina S, Singh B, Dadhwal DS, Dogra V, et al. A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: a structured summary of a study protocol for a randomized controlled trial. Trials. 2021; 22: 451.","DOI":"10.1186\/s13063-021-05361-y"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"Procter BC, Ross C, Pickard V, Smith E, Hanson C, McCullough PA. Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Reviews in Cardiovascular Medicine. 2020; 21: 611\u2013614.","DOI":"10.31083\/j.rcm.2020.04.260"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"Procter, MD BC, APRN, FNP-C CRM, PA-C, MPAS VP, PA-C, MPAS ES, PA-C, MPAS CH, McCullough, MD, MPH PA. Early Ambulatory Multidrug Therapy Reduces Hospitalization and Death in High-Risk Patients with SARS-CoV-2 (COVID-19). International Journal of Innovative Research in Medical Science. 2021; 6: 219\u2013221.","DOI":"10.23958\/ijirms\/vol06-i03\/1100"},{"key":"ref118","doi-asserted-by":"crossref","unstructured":"Derwand R, Scholz M, Zelenko V. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. International Journal of Antimicrobial Agents. 2020; 56: 106214.","DOI":"10.1016\/j.ijantimicag.2020.106214"},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"Boriskin Y, Leneva I, Pecheur E-, Polyak S. Arbidol: a Broad-Spectrum Antiviral Compound that Blocks Viral Fusion. Current Medicinal Chemistry. 2008; 15: 997\u20131005.","DOI":"10.2174\/092986708784049658"},{"key":"ref120","doi-asserted-by":"crossref","unstructured":"Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: a retrospective cohort study. Journal of Infection. 2020; 81: e1\u2013e5.","DOI":"10.1016\/j.jinf.2020.03.002"},{"key":"ref121","doi-asserted-by":"crossref","unstructured":"Chen J, Lin S, Niu C, Xiao Q. Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study. Expert Review of Respiratory Medicine. 2021; 15: 257\u2013265.","DOI":"10.1080\/17476348.2020.1822741"},{"key":"ref122","doi-asserted-by":"crossref","unstructured":"Yuan S, Yin X, Meng X, Chan JF, Ye Z, Riva L, et al. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Nature. 2021; 593: 418\u2013423.","DOI":"10.1038\/s41586-021-03431-4"},{"key":"ref123","doi-asserted-by":"crossref","unstructured":"Gendrot M, Duflot I, Boxberger M, Delandre O, Jardot P, Le Bideau M, et al. Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: in vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate. International Journal of Infectious Diseases. 2020; 99: 437\u2013440.","DOI":"10.1016\/j.ijid.2020.08.032"},{"key":"ref124","doi-asserted-by":"crossref","unstructured":"Shionoya K, Yamasaki M, Iwanami S, Ito Y, Fukushi S, Ohashi H, et al. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro. Frontiers in Microbiology. 2021; 12: 651403.","DOI":"10.3389\/fmicb.2021.651403"},{"key":"ref125","doi-asserted-by":"crossref","unstructured":"Fintelman-Rodrigues N, Sacramento CQ, Ribeiro Lima C, Souza da Silva F, Ferreira AC, Mattos M, et al. Atazanavir, alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production. Antimicrobial Agents and Chemotherapy. 2020; 64: e00825-20.","DOI":"10.1128\/AAC.00825-20"},{"key":"ref126","doi-asserted-by":"crossref","unstructured":"Purwati, Miatmoko A, Nasronudin, Hendrianto E, Karsari D, Dinaryanti A, et al. An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and\/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia. PLoS ONE. 2021; 16: e0252302.","DOI":"10.1371\/journal.pone.0252302"},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir\u2013Ritonavir in Adults Hospitalized with Severe Covid-19. New England Journal of Medicine. 2020; 382: 1787\u20131799.","DOI":"10.1056\/NEJMc2008043"},{"key":"ref128","doi-asserted-by":"crossref","unstructured":"Ahmad I, Alam M, Saadi R, Mahmud S, Saadi E. Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities. medRxiv. 2020. (in press)","DOI":"10.1101\/2020.05.18.20066902"},{"key":"ref129","doi-asserted-by":"crossref","unstructured":"Mahmud R, Rahman MM, Alam I, Ahmed KGU, Kabir AKMH, Sayeed SKJB, et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. Journal of International Medical Research. 2021; 49: 030006052110135.","DOI":"10.1177\/03000605211013550"},{"key":"ref130","doi-asserted-by":"crossref","unstructured":"Szolnoky G. Further aspects of doxycycline therapy in COVID-19. Dermatologic Therapy. 2020; 33: e13810.","DOI":"10.1111\/dth.13810"},{"key":"ref131","doi-asserted-by":"crossref","unstructured":"Gautam SS, Gautam CS, Garg VK, Singh H. Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection. Expert Review of Clinical Pharmacology. 2020; 13: 1183\u20131190.","DOI":"10.1080\/17512433.2020.1832889"},{"key":"ref132","doi-asserted-by":"crossref","unstructured":"Schloer S, Brunotte L, Mecate\u2010Zambrano A, Zheng S, Tang J, Ludwig S, et al. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS\u2010CoV\u20102 infection in vitro. British Journal of Pharmacology. 2021; 178: 2339\u20132350.","DOI":"10.1111\/bph.15418"},{"key":"ref133","doi-asserted-by":"crossref","unstructured":"XIA L, SHI Y, SU J, Friedemann T, TAO Z, Lu Y, et al. Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study. Phytomedicine. 2021; 85: 153390.","DOI":"10.1016\/j.phymed.2020.153390"},{"key":"ref134","doi-asserted-by":"crossref","unstructured":"Gopal M, Padayatchi N, Metcalfe JZ, O\u2019Donnell MR. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease. 2013; 17: 1001\u20131007.","DOI":"10.5588\/ijtld.12.0144"},{"key":"ref135","doi-asserted-by":"crossref","unstructured":"Schloer S, Goretzko J, Rescher U. Repurposing Antifungals for Host-Directed Antiviral Therapy? Pharmaceuticals. 2022; 15: 212.","DOI":"10.3390\/ph15020212"},{"key":"ref136","doi-asserted-by":"crossref","unstructured":"Van Damme E, De Meyer S, Bojkova D, Ciesek S, Cinatl J, De Jonghe S, et al. In vitro activity of itraconazole against SARS\u2010CoV\u20102. Journal of Medical Virology. 2021; 93: 4454\u20134460.","DOI":"10.1002\/jmv.26917"},{"key":"ref137","doi-asserted-by":"crossref","unstructured":"Liesenborghs L, Spriet I, Jochmans D, Belmans A, Gyselinck I, Teuwen L, et al. Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. EBioMedicine. 2021; 66: 103288.","DOI":"10.1016\/j.ebiom.2021.103288"},{"key":"ref138","doi-asserted-by":"crossref","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020; 30: 269\u2013271.","DOI":"10.1038\/s41422-020-0282-0"},{"key":"ref139","doi-asserted-by":"crossref","unstructured":"Moyle G, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Medicine. 2001; 2: 105\u2013113.","DOI":"10.1046\/j.1468-1293.2001.00063.x"},{"key":"ref140","doi-asserted-by":"crossref","unstructured":"Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, et al. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-\u03b21b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018; 19: 81.","DOI":"10.1186\/s13063-017-2427-0"},{"key":"ref141","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020; 396: 1345\u20131352.","DOI":"10.1016\/S0140-6736(20)32013-4"},{"key":"ref142","doi-asserted-by":"crossref","unstructured":"Sankar J, Dhochak N, Kabra SK, Lodha R. COVID-19 in Children: Clinical Approach and Management. The Indian Journal of Pediatrics. 2020; 87: 433\u2013442.","DOI":"10.1007\/s12098-020-03292-1"},{"key":"ref143","doi-asserted-by":"crossref","unstructured":"Singh H, Kakkar AK, Chauhan P. Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges. Expert Review of Anti-Infective Therapy. 2020; 18: 997\u20131003.","DOI":"10.1080\/14787210.2020.1782190"},{"key":"ref144","doi-asserted-by":"crossref","unstructured":"Sodhi M, Etminan M. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19. Pharmacotherapy. 2020; 40: 487\u2013488.","DOI":"10.1002\/phar.2395"},{"key":"ref145","doi-asserted-by":"crossref","unstructured":"Jacobs L, Johnson KP. A Brief History of the Use of Interferons as Treatment of Multiple Sclerosis. Archives of Neurology. 1994; 51: 1245\u20131252.","DOI":"10.1001\/archneur.1994.00540240089022"},{"key":"ref146","doi-asserted-by":"crossref","unstructured":"Lu C, Chen M, Lee W, Chang Y. Potential therapeutic agents against COVID-19: what we know so far. Journal of the Chinese Medical Association. 2020; 83: 534\u2013536.","DOI":"10.1097\/JCMA.0000000000000318"},{"key":"ref147","doi-asserted-by":"crossref","unstructured":"Dastan F, Nadji SA, Saffaei A, Marjani M, Moniri A, Jamaati H, et al. Subcutaneous administration of interferon beta-1a for COVID-19: a non-controlled prospective trial. International Immunopharmacology. 2020; 85: 106688.","DOI":"10.1016\/j.intimp.2020.106688"},{"key":"ref148","doi-asserted-by":"crossref","unstructured":"Baghaei P, Dastan F, Marjani M, Moniri A, Abtahian Z, Ghadimi S, Valizadeh M, Heshmatnia J, Sadat Mirenayat M, Abedini A, Kiani A, Eslaminejad A, MohammadReza Hashemian S, Jamaati H, Zali A, Akbar Velayati A, Tabarsi P. Combination therapy of IFN\u03b21 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients. International Immunopharmacology. 2021; 92: 107329.","DOI":"10.1016\/j.intimp.2020.107329"},{"key":"ref149","doi-asserted-by":"crossref","unstructured":"Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, et al. An open-label randomized controlled trial of the effect of lopinavir\/ritonavir, lopinavir\/ritonavir plus IFN-\u03b2-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clinical Microbiology and Infection. 2021; 27: 1826\u20131837.","DOI":"10.1016\/j.cmi.2022.04.016"},{"key":"ref150","doi-asserted-by":"crossref","unstructured":"Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, et al. Interferon-\u03b12b Treatment for COVID-19. Frontiers in Immunology. 2020; 11: 1061.","DOI":"10.3389\/fimmu.2020.01061"},{"key":"ref151","doi-asserted-by":"crossref","unstructured":"Wang B, Li D, Liu T, Wang H, Luo F, Liu Y. Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study. BMC Infectious Diseases. 2020; 20: 723.","DOI":"10.1186\/s12879-020-05425-5"},{"key":"ref152","doi-asserted-by":"crossref","unstructured":"Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395: 1695\u20131704.","DOI":"10.1016\/S0140-6736(20)31042-4"},{"key":"ref153","doi-asserted-by":"crossref","unstructured":"Ianevski A, Yao R, Lysvand H, Gr\u00f8deland G, Legrand N, Oksenych V, et al. Nafamostat-Interferon-\u03b1 Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2. Viruses. 2021; 13: 1768.","DOI":"10.3390\/v13091768"},{"key":"ref154","doi-asserted-by":"crossref","unstructured":"Ianevski A, Yao R, Zusinaite E, Lello LS, Wang S, Jo E, et al. Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections. Viruses. 2021; 13: 2489.","DOI":"10.3390\/v13122489"},{"key":"ref155","doi-asserted-by":"crossref","unstructured":"Ali S, Khalid S, Afridi M, Akhtar S, Khader YS, Akhtar H. Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome. JMIR Public Health and Surveillance. 2021; 7: e27609.","DOI":"10.2196\/27609"},{"key":"ref156","doi-asserted-by":"crossref","unstructured":"Brown LK, Moran E, Goodman A, Baxendale H, Bermingham W, Buckland M, et al. Treatment of chronic or relapsing COVID-19 in immunodeficiency. Journal of Allergy and Clinical Immunology. 2022; 149: 557\u2013561.e1.","DOI":"10.1016\/j.jaci.2021.10.031"},{"key":"ref157","doi-asserted-by":"crossref","unstructured":"Jassem J, Marek-Trzonkowska NM, Smiatacz T, Arcimowicz \u0141, Papak I, Jassem E, Zaucha JM. Successful Treatment of Persistent SARS-CoV-2 Infection in a B-Cell Depleted Patient with Activated Cytotoxic T and NK Cells: A Case Report. International Journal of Molecular Sciences. 2021; 22: 10934.","DOI":"10.3390\/ijms222010934"},{"key":"ref158","doi-asserted-by":"crossref","unstructured":"Malsy J, Veletzky L, Heide J, Hennigs A, Gil-Ibanez I, Stein A, et al. Sustained Response after Remdesivir and Convalescent Plasma Therapy in a B-Cell\u2013Depleted Patient with Protracted Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases. 2021; 73: e4020\u2013e4024.","DOI":"10.1093\/cid\/ciaa1637"},{"key":"ref159","doi-asserted-by":"crossref","unstructured":"Helleberg M, Niemann CU, Moestrup KS, Kirk O, Lebech A, Lane C, et al. Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy. The Journal of Infectious Diseases. 2020; 222: 1103\u20131107.","DOI":"10.1093\/infdis\/jiaa446"},{"key":"ref160","doi-asserted-by":"crossref","unstructured":"Iaboni A, Wong N, Betschel SD. A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma. Journal of Clinical Immunology. 2021; 41: 923\u2013925.","DOI":"10.1007\/s10875-021-00983-y"},{"key":"ref161","doi-asserted-by":"crossref","unstructured":"Giudice V, Pagliano P, Vatrella A, Masullo A, Poto S, Polverino BM, et al. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study. Frontiers in Pharmacology. 2020; 11: 857.","DOI":"10.3389\/fphar.2020.00857"},{"key":"ref162","doi-asserted-by":"crossref","unstructured":"Rosa-Guerrero P, Trujillo-Aguilera A, Molina J, Navas A, L\u00f3pez-Mart\u00edn C, Jurado A, et al. Case Report: Successful Response to Intravenous Immunoglobulin and Steroid Pulses in a Renal Transplant Recipient With Severe Covid-19 Disease and Associated Acute Allograft Failure. Frontiers in Immunology. 2021; 12: 671013.","DOI":"10.3389\/fimmu.2021.671013"},{"key":"ref163","doi-asserted-by":"crossref","unstructured":"Sancho-L\u00f3pez A, Caballero-Bermejo AF, Ruiz-Antor\u00e1n B, M\u00fa\u00f1ez Rubio E, Garc\u00eda Gasalla M, Buades J, et al. Efficacy and Safety of Sarilumab in patients with COVID19 Pneumonia: a Randomized, Phase III Clinical Trial (SARTRE Study). Infectious Diseases and Therapy. 2021; 10: 2735\u20132748.","DOI":"10.1007\/s40121-021-00543-2"},{"key":"ref164","doi-asserted-by":"crossref","unstructured":"Wyler E, Adler JM, Eschke K, Teixeira Alves G, Peidli S, Pott F, et al. Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single-cell transcriptomics. Molecular Therapy. 2022; 30: 1952\u20131965.","DOI":"10.1016\/j.ymthe.2022.03.014"},{"key":"ref165","doi-asserted-by":"crossref","unstructured":"Cai Y, Xu W, Gu C, Cai X, Qu D, Lu L, et al. Griffithsin with a Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with a Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit. Virologica Sinica. 2020; 35: 857\u2013860.","DOI":"10.1007\/s12250-020-00305-3"},{"key":"ref166","doi-asserted-by":"crossref","unstructured":"Akhter J, Qu\u00e9rom\u00e8s G, Pillai K, Kepenekian V, Badar S, Mekkawy AH, et al. The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2. Viruses. 2021; 13: 425.","DOI":"10.3390\/v13030425"},{"key":"ref167","doi-asserted-by":"crossref","unstructured":"Coelho Dos Reis JGA, Ferreira GM, Louren\u00e7o AA, Ribeiro \u00c1L, da Mata CPDSM, de Melo Oliveira P, et al. Ex-vivo mucolytic and anti-inflammatory activity of BromAc in tracheal aspirates from COVID-19. Biomedicine & Pharmacotherapy. 2022; 148: 112753.","DOI":"10.1016\/j.biopha.2022.112753"},{"key":"ref168","doi-asserted-by":"crossref","unstructured":"Kritis P, Karampela I, Kokoris S, Dalamaga M. The combination of bromelain and curcumin as an immune-boosting nutraceutical in the prevention of severe COVID-19. Metabolism Open. 2020; 8: 100066.","DOI":"10.1016\/j.metop.2020.100066"},{"key":"ref169","doi-asserted-by":"crossref","unstructured":"Lusvarghi S, Bewley CA. Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential. Viruses. 2016; 8: 296.","DOI":"10.3390\/v8100296"},{"key":"ref170","doi-asserted-by":"crossref","unstructured":"Soni VK, Mehta A, Ratre YK, Tiwari AK, Amit A, Singh RP, et al. Curcumin, a traditional spice component, can hold the promise against COVID-19? European Journal of Pharmacology. 2020; 886: 173551.","DOI":"10.1016\/j.ejphar.2020.173551"},{"key":"ref171","doi-asserted-by":"crossref","unstructured":"Sagar S, Rathinavel AK, Lutz WE, Struble LR, Khurana S, Schnaubelt AT, et al. Bromelain inhibits SARS-CoV-2 infection in VeroE6 cells. bioRxiv. 2020. (in press)","DOI":"10.1101\/2020.09.16.297366"},{"key":"ref172","doi-asserted-by":"crossref","unstructured":"Troyano-Hern\u00e1ez P, Reinosa R, Holgu\u00edn \u00c1. Evolution of SARS-CoV-2 Envelope, Membrane, Nucleocapsid, and Spike Structural Proteins from the Beginning of the Pandemic to September 2020: A Global and Regional Approach by Epidemiological Week. Viruses. 2021; 13: 243.","DOI":"10.3390\/v13020243"},{"key":"ref173","doi-asserted-by":"crossref","unstructured":"Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host & Microbe. 2021; 29: 44\u201357.e9.","DOI":"10.1016\/j.chom.2020.11.007"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/9\/10.31083\/j.fbl2709257","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T12:08:27Z","timestamp":1732709307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/9\/10.31083\/j.fbl2709257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":173,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"alternative-id":["S2768-6701(22)00606-2"],"URL":"https:\/\/doi.org\/10.31083\/j.fbl2709257","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"type":"print","value":"2768-6701"},{"type":"electronic","value":"2768-6698"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"article-number":"257"}}